PSMD13 (Proteasome 26S Subunit, Non-ATPase 13) is an integral component of the 26S proteasome complex, which plays a critical role in the ubiquitin-proteasome system (UPS). The UPS is essential for the degradation of misfolded, damaged, or regulatory proteins, thereby maintaining cellular homeostasis, regulating cell cycle progression, and controlling various signaling pathways. PSMD13 contributes specifically to the assembly and stability of the 19S regulatory particle, part of the 26S proteasome, which recognizes ubiquitinated proteins, unfolds them, and translocates them to the 20S core particle for degradation. This function is vital for the selective degradation of proteins, allowing the cell to respond to stress, regulate gene expression, and remove damaged or excess proteins efficiently. Given its pivotal role in protein turnover, PSMD13 is crucial for proper cellular function and health, impacting processes ranging from cell growth and division to stress responses and immune regulation.
The inhibition of PSMD13 can significantly impact the proteasome's functionality, potentially leading to the accumulation of ubiquitinated proteins that are not properly degraded. This accumulation can disrupt cellular processes and lead to cellular stress or toxicity, which is relevant in the context of diseases such as neurodegenerative disorders, where protein aggregation is a hallmark. Inhibiting PSMD13 involves targeting this subunit to disrupt its role in proteasome assembly or function. One approach might involve small molecule inhibitors that bind specifically to PSMD13, altering its interaction with other proteasome components or with ubiquitinated substrates, thereby hindering the assembly or operational efficiency of the 19S regulatory particle. Another strategy could include the use of genetic tools like siRNA or CRISPR-Cas9 to reduce the expression of the PSMD13 gene, thereby decreasing its availability in the cell and affecting the overall composition and function of the proteasome. Such inhibition not only provides a tool to study the fundamental biology of the proteasome and its role in cellular regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that directly targets the 26S proteasome subunits, reducing PSMD13's catalytic activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Another proteasome inhibitor that has a selective and irreversible binding to 20S proteasome subunits, impacting PSMD13's enzymatic properties. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Blocks the ubiquitin-proteasome pathway by inhibiting the 26S proteasome, leading to a buildup of proteins that PSMD13 would usually help degrade. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor that impairs the 20S core particle, diminishing PSMD13's ability to execute its proteolytic functions. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Covalently binds to the 20S proteasome subunit, directly inhibiting PSMD13 by preventing its assembly into functional proteasomes. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
Broad-spectrum deubiquitinase inhibitor that indirectly impacts PSMD13 by altering the ubiquitin-proteasome system. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Inhibits the proteasome's β-subunits, directly disrupting PSMD13's catalytic activities in protein degradation. | ||||||